In a patient with presumed acute myeloid leukemia (AML) who develops a chest infection one week after admission, should chemotherapy be continued or paused according to guidelines?

Management of Chemotherapy in AML Patients with Chest Infection After 1 Week of Admission

In a presumed AML patient who develops a chest infection one week after admission, chemotherapy should generally be continued while aggressively treating the infection with broad-spectrum antibiotics and appropriate supportive care, unless the patient is clinically unstable or deteriorating. 1

Clinical Decision Framework

The key distinction is whether the infection develops before or during/after chemotherapy:

If Infection Develops BEFORE Starting Chemotherapy

The ESMO AML guidelines explicitly state that chemotherapy should be delayed until active infection has been treated when infection is identified at diagnosis 2. This recommendation applies to:

• Patients being evaluated for initial induction therapy
• Those with active infection detected on pre-treatment workup (chest CT, abdominal imaging)
• Patients requiring careful clinical and hematological assessment before treatment initiation

However, your scenario describes infection developing after 1 week of admission, which implies chemotherapy has likely already been initiated.

If Infection Develops DURING Chemotherapy (Your Scenario)

Continue chemotherapy while treating the infection aggressively 1. The management algorithm is:

At 48 Hours After Fever Onset:

If clinically stable:

• Continue initial broad-spectrum antibacterial therapy
• Maintain chemotherapy schedule
• Monitor closely for deterioration

If clinically unstable:

• Rotate or broaden antibacterial coverage
• Consider adding glycopeptide or switching to carbapenem plus glycopeptide
• Seek urgent infectious disease consultation
• Still continue chemotherapy unless patient is severely deteriorating 1

At 4-6 Days of Persistent Fever:

• Obtain chest and abdominal CT imaging to exclude fungal infection or abscesses
• Initiate empiric antifungal therapy 1
• Continue chemotherapy unless contraindicated by clinical deterioration

Duration of Antibacterial Therapy

The guidelines provide clear stopping rules that allow chemotherapy continuation 1:

Discontinue antibiotics when:

• Neutrophil count ≥0.5 × 10⁹/L AND
• Patient afebrile for 48 hours AND
• Blood cultures negative

Continue antibiotics when:

• Neutrophil count ≤0.5 × 10⁹/L
• Patient afebrile for 5-7 days without complications
• Exception: In acute leukemia patients, antibiotics often continued for up to 10 days or until neutrophil recovery, even if afebrile 1

Critical Caveats

When to Consider Holding Chemotherapy:

1. Severe clinical deterioration despite appropriate antimicrobial therapy
2. Septic shock requiring vasopressor support
3. Multi-organ failure developing from infection
4. Documented invasive fungal infection requiring prolonged antifungal therapy before proceeding

Common Pitfalls to Avoid:

• Do not reflexively stop chemotherapy for fever alone in neutropenic AML patients—this is expected and manageable 3
• Do not delay appropriate imaging (chest/abdominal CT) if fever persists beyond 4-6 days 1
• Do not underestimate infection risk in older patients (≥60-65 years) who are more susceptible to severe infections 2
• Do not forget antifungal coverage if fever persists despite appropriate antibacterial therapy 1

Practical Management Algorithm

1. Day 1 of fever: Start broad-spectrum antibiotics immediately (e.g., antipseudomonal beta-lactam ± aminoglycoside)
2. Day 2-3: Reassess clinical status; if stable, continue current therapy and chemotherapy
3. Day 4-6: If fever persists, obtain CT chest/abdomen and consider empiric antifungal therapy
4. Throughout: Continue chemotherapy unless patient becomes hemodynamically unstable or develops organ failure

Rationale

The guidelines emphasize that infectious complications during induction are expected and manageable 2. Stopping chemotherapy prematurely compromises the chance of achieving complete remission, which is the primary determinant of survival in AML. The modern approach prioritizes aggressive supportive care and antimicrobial therapy while maintaining the chemotherapy schedule, as this strategy has been shown to be safe and effective in experienced centers with adequate multidisciplinary infrastructure 2.

The mortality benefit from achieving complete remission far outweighs the infection risk when appropriate supportive care is provided 2. Only in cases of severe clinical deterioration or life-threatening infection should chemotherapy be interrupted.